{
    "id": 26189,
    "cites": 18,
    "cited_by": 0,
    "reference": [
        "1. Australian Pesticides and Veterinary Medicines Authority. Quantity of Antimicrobial Products Sold for Veterinary Use in Australia.; 2014. 2. Van Boeckel TP, Brower C, Gilbert M, et al. Global trends in antimicrobial use in food animals.",
        "Proc Natl Acad Sci U S A. 2015;112(18):5649-5654. doi:10.1073/pnas.1503141112. 3. Brown G, Layton DF. Resistance economics: social cost and the evolution of antibiotic resistance.",
        "4. Burnham JP, Olsen MA, Kollef MH. Re-estimating annual deaths due to multidrug-resistant organism infections. Infect Control Hosp Epidemiol. 2019;40(1):112-113. doi:10.1017/ice.2018.304.",
        "5. California Legislative Body. Senate Bill No. 27 Livestock: Use of Antimicrobial Drugs. California Legislative Counsel; 2015.",
        "https://leginfo.legislature.ca.gov/faces/billTextClient.xhtml?bill_id=201520160SB27 6. Cassini A, H\u00c3\u0083\u00c2\u00b6gberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56-66.",
        "7. CDC, FDA. NARMS 1999 Annual Report.; 1999.",
        "8. CIPARS. Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS), 2016 Annual Report.; 2016.",
        "9. Cohen B, Larson EL, Stone PW, Neidell M, Glied SA. Factors Associated With Variation in Estimates of the Cost of Resistant Infections. Med Care. 2010;48(9):767-775.",
        "http://www.fda.gov/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/d 20. FDA/CVM. Human Health Impact of Fluoroquinolone Resistant Campylobacter Attributed to the Consumption of Chicken.; 2000.",
        "estimates for 2013 for Salmonella, Escherichia coli O157, Listeria monocytogenes, and Campylobacter using multi-year outbreak surveillance data, United States. GA and D. IFSAC Proj. 2017;(November):1-13. https://www.cdc.gov/foodsafety/pdfs/IFSAC2013FoodborneillnessSourceEstimates -508.pdf.",
        "Accessed May 7, 2019. 33. Korinek A. The Externalities of Antimicrobial Resistance, http://www.korinek.com/AMR.",
        "https://www.fda.gov/AnimalVeterinary/SafetyHealth/AntimicrobialResistance/NationalAntimicro bialRe. Accessed August 16, 2018.",
        "http://apps.who.int/iris/bitstream/handle/10665/112642/9789241564748_eng.pdf;jsessionid=C08C 60691635B5D4635DB3D050DB403C?sequence=1. Accessed August 16, 2018.",
        "http://www.oie.int/fileadmin/Home/eng/Our_scientific_expertise/docs/pdf/AMR/A_AMR_RESO_ 2017.pdf. Accessed May 27, 2019.",
        "The OECD report additionally projected that by 2050, 1.75 million disability-adjusted-life-years (DALYs) will be lost annually due to AMR, across all modelled countries (EU/EEA, U.S., Canada, Australia).(43) In absolute terms, the OECD model estimated that the USA would experience the highest health burden of AMR among OECD countries, with approximately 1 million deaths attributable to AMR infections and an average of 724,000 DALY\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s lost per year in the USA, by 2050.(43)",
        "Eurasia, and Sub-Saharan Africa $2 trillion - $6.1 trillion USD, depending on simulation Healthcare perspective Impact on healthcare costs by 2050: 0.33 trillion-$1.2 trillion USD, depending on simulation OECD(43) 8 bacteria and a total of 17 AMR-bacteria combinations Bacteria included: Acinetobacter spp.",
        "SU for quinolones, cephalosporins and broad spectrum penicillins Thailand: $0.1 USD per SU for macrolides - $0.7 USD per SU for quinolones, cephalosporins and broad spectrum penicillins Meta-analysis of AMR-pathogen specific estimates Wozniak et al., 2018(73) A review of 14 studies/reports which concludes high quality estimates for: MRSA, 3GCR-E, ESBLP-E BSI Various 20122016 NA Healthcare perspective LOS: MRSA: +2.54 days (-3.198.",
        "68) (Stewardson, 2016) ESBLR-E: +6.8 days (Stewardson 2013) Excess healthcare cost: MRSA: \u00c3\u00a2\u00e2\u0080\u009a\u00c2\u00ac1600 EUR 3GCR-E: \u00c3\u00a2\u00e2\u0080\u009a\u00c2\u00ac3200 EUR ESBLR-E: 9473 CHF Naylor et al., 2018(40) Reviewed 214 studies, which included estimates on various AMR-pathogens BSI Pneumonia Meningitis Various Various 20132015 Patient burden of AMR: 48% (85/177) of studies found that AMR had a significant impact on mortality LOS: 69% (44/64) of studies found that AMR had a significant impact on LOS. LOS ranged from +2.5 days to +20 days depending on AMRpathogen and country Incremental healthcare cost per case: Estimates ranged from nonsignificant to 88,150 USD depending on AMR-pathogen and country  S Table 2. Total amounts of antimicrobial agents applicable mainly for food-producing animals based on electronically available country reports."
    ]
}